Comparison of platelet-rich plasma injection versus corticosteroid injection for the treatment of frozen shoulder in Asia: A systematic review and meta-analysis of randomized controlled trials.

IF 2.4 Q2 MEDICINE, GENERAL & INTERNAL
Tzu Chi Medical Journal Pub Date : 2026-01-12 eCollection Date: 2026-04-01 DOI:10.4103/tcmj.TCMJ-D-25-00008
Hendrawan Chandra Kusuma, Mario Daniel Simatupang, Jesica Ery, Sabrina Danica, Billy Leoprayogo, Woo-Yong Lee
{"title":"Comparison of platelet-rich plasma injection versus corticosteroid injection for the treatment of frozen shoulder in Asia: A systematic review and meta-analysis of randomized controlled trials.","authors":"Hendrawan Chandra Kusuma, Mario Daniel Simatupang, Jesica Ery, Sabrina Danica, Billy Leoprayogo, Woo-Yong Lee","doi":"10.4103/tcmj.TCMJ-D-25-00008","DOIUrl":null,"url":null,"abstract":"<p><p>This study investigates the therapeutic performance of intra-articular platelet-rich plasma (PRP) versus intra-articular corticosteroid injections, specifically evaluating outcomes within Asian demographic groups. This review was conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses 2020 statement. We assessed study quality with the Cochrane Risk of Bias 2 (RoB2) tool, Review Manager (RevMan) 5.4 for the meta-analysis, and GRADE analysis to assess the certainty of evidence. Our review includes 14 studies, with 11 analyzed through meta-analysis, involving 1295 patients. However, the included studies were limited to populations from India and Pakistan. In the short term, there were no significant differences between the PRP and corticosteroid groups in pain and disability scores. However, the PRP group showed significantly greater improvements in some aspects of range of motion (ROM). In the mid-term, the PRP group had significantly lower Visual Analog Scale (VAS) (mean difference [MD]: -9.67; 95% confidence interval [CI]: -19.36, -0.08), Disabilities of the Arm, Shoulder and Hand (DASH) (MD: -10.47, 95% CI: -20.82, -0.13), and Shoulder Pain and Disability Index (SPADI) scores (MD: -17.92, 95% CI: -28.14, -7.69) compared to corticosteroids, as well as greater ROM improvements across multiple measures (all <i>P</i> < 0.05). In the mid-long term, pooled analysis indicated that VAS (MD: -21.13, 95% CI: -33.35, -8.91), DASH (MD: -10.25, 95% CI: -16.87, -3.64), and SPADI scores (MD: -17.81, 95% CI: -30.89, -4.73) were significantly lower in the PRP group than in corticosteroids. Although PRP shows no immediate advantage over corticosteroids in pain and disability, it improves short-term ROM and provides superior mid- to mid-long-term outcomes. However, results should be interpreted cautiously due to high heterogeneity, varying RoB, and moderate to very low GRADE certainty.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"38 2","pages":"164-173"},"PeriodicalIF":2.4000,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167082/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tzu Chi Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/tcmj.TCMJ-D-25-00008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

This study investigates the therapeutic performance of intra-articular platelet-rich plasma (PRP) versus intra-articular corticosteroid injections, specifically evaluating outcomes within Asian demographic groups. This review was conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses 2020 statement. We assessed study quality with the Cochrane Risk of Bias 2 (RoB2) tool, Review Manager (RevMan) 5.4 for the meta-analysis, and GRADE analysis to assess the certainty of evidence. Our review includes 14 studies, with 11 analyzed through meta-analysis, involving 1295 patients. However, the included studies were limited to populations from India and Pakistan. In the short term, there were no significant differences between the PRP and corticosteroid groups in pain and disability scores. However, the PRP group showed significantly greater improvements in some aspects of range of motion (ROM). In the mid-term, the PRP group had significantly lower Visual Analog Scale (VAS) (mean difference [MD]: -9.67; 95% confidence interval [CI]: -19.36, -0.08), Disabilities of the Arm, Shoulder and Hand (DASH) (MD: -10.47, 95% CI: -20.82, -0.13), and Shoulder Pain and Disability Index (SPADI) scores (MD: -17.92, 95% CI: -28.14, -7.69) compared to corticosteroids, as well as greater ROM improvements across multiple measures (all P < 0.05). In the mid-long term, pooled analysis indicated that VAS (MD: -21.13, 95% CI: -33.35, -8.91), DASH (MD: -10.25, 95% CI: -16.87, -3.64), and SPADI scores (MD: -17.81, 95% CI: -30.89, -4.73) were significantly lower in the PRP group than in corticosteroids. Although PRP shows no immediate advantage over corticosteroids in pain and disability, it improves short-term ROM and provides superior mid- to mid-long-term outcomes. However, results should be interpreted cautiously due to high heterogeneity, varying RoB, and moderate to very low GRADE certainty.

富血小板血浆注射与皮质类固醇注射治疗亚洲肩周炎的比较:随机对照试验的系统回顾和荟萃分析。
本研究调查了关节内富血小板血浆(PRP)与关节内皮质类固醇注射的治疗效果,特别评估了亚洲人群的治疗效果。本综述按照2020年系统评价和荟萃分析声明的首选报告项目进行。我们使用Cochrane Risk of Bias 2 (RoB2)工具评估研究质量,meta分析使用Review Manager (RevMan) 5.4, GRADE分析评估证据的确定性。我们的综述包括14项研究,其中11项通过荟萃分析进行分析,涉及1295例患者。然而,纳入的研究仅限于来自印度和巴基斯坦的人群。在短期内,PRP组和皮质类固醇组在疼痛和残疾评分方面没有显著差异。然而,PRP组在活动范围(ROM)的某些方面表现出明显更大的改善。中期,与皮质类固醇相比,PRP组的视觉模拟量表(VAS)(平均差值[MD]: -9.67; 95%可信区间[CI]: -19.36, -0.08)、手臂、肩膀和手的残疾(DASH) (MD: -10.47, 95% CI: -20.82, -0.13)和肩痛和残疾指数(SPADI)评分(MD: -17.92, 95% CI: -28.14, -7.69)显著降低,多个测量方法的ROM改善更大(均P < 0.05)。在中长期,合并分析表明,PRP组的VAS (MD: -21.13, 95% CI: -33.35, -8.91)、DASH (MD: -10.25, 95% CI: -16.87, -3.64)和SPADI评分(MD: -17.81, 95% CI: -30.89, -4.73)显著低于皮质类固醇组。虽然PRP在疼痛和残疾方面没有表现出比皮质类固醇更直接的优势,但它改善了短期ROM,并提供了优越的中长期结果。然而,由于高异质性、不同的RoB和中度至极低的GRADE确定性,结果应谨慎解释。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Tzu Chi Medical Journal
Tzu Chi Medical Journal MEDICINE, GENERAL & INTERNAL-
CiteScore
3.40
自引率
0.00%
发文量
44
审稿时长
13 weeks
期刊介绍: The Tzu Chi Medical Journal is the peer-reviewed publication of the Buddhist Compassion Relief Tzu Chi Foundation, and includes original research papers on clinical medicine and basic science, case reports, clinical pathological pages, and review articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书